Combined therapy with inhaled nitric oxide and intravenous vasodilators during acute and chronic experimental pulmonary hypertension

Anesthesia and Analgesia

Volumn 89, Issue 1, 1999, Pages 152-158

  Aranda, Margaret ^a   Bradford, Katherine Kilroy ^a   Pearl, Ronald G ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PROSTACYCLIN; VASODILATOR AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL PRESSURE; ARTICLE; DRUG EFFECT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; TREATMENT OUTCOME;

ACUTE DISEASE; ADENOSINE; ADMINISTRATION, INHALATION; ANIMALS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; EPOPROSTENOL; HYPERTENSION, PULMONARY; INJECTIONS, INTRAVENOUS; MALE; NITRIC OXIDE; NITROPRUSSIDE; RATS; RATS, SPRAGUE-DAWLEY; VASODILATOR AGENTS;

EID: 0032976140     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199907000-00027     Document Type: Article

References (32)

1. Lowenstein CH, Dinerman JL, Snyder SH. Nitric oxide: a physiologic messenger. Ann Intern Med 1994;120:227-3.
2. Fineman JR, Heymann JA, Soifer SJ. N-nitro-L-arginine attenuates endothelium-dependent pulmonary vasodilation in lambs. Am J Physiol 1991;260:H1299-306.
3. Greenberg B, Rhoden K, Barnes PJ. Endothelium-dependent relaxation of human pulmonary arteries. Am J Physiol 1987;252: H434-8.
4. Ogura H, Cioffi WG, Offner PJ, et al. Effect of inhaled nitric oxide on pulmonary function after sepsis in a swine model. Surgery 1994;116:313-21.
5. Pison U, Lopez FA, Heidelmeyer CF, et al. Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction without impairing gas exchange. J Appl Physiol 1993;74:1287-92.
6. Aranda M, Pearl RG. The pharmacology and physiology of nitric oxide: understanding its use in anesthesia and critical care medicine. Anesth Clin North Am 1998;16:235-57.
7. Bigatello LM, Hurford WE, Kacmarek RM, et al. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Anesthesiology 1994;80:761-70.
8. Krafft P, Fridrich P, Fitzgerald RD, et al. Effectiveness of nitric oxide inhalation in septic ARDS. Chest 1996;109:486-93.
9. Rich GF, Murphy GD Jr, Roos CM, Johns RA. Inhaled nitric oxide: selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 1993;78:1028-35.
10. 2, and prostacyclin. Pharmacol Rev 1979;30:293-31.
11. Nootens M, Schrader B, Kaufmann E, et al. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995;107:54-7.
12. 2 adenosine receptors in vivo in feline pulmonary vascular bed. Am J Physiol 1996;270:H610-9.
13. 2 receptor. Anesth Analg 1994;79:46-51.
14. Stinger RB, Iacopino VJ, Alter I, et al. Catheterization of the pulmonary artery in the closed-chest rat. J Appl Physiol 1981; 51:1047-50.
15. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:384-9.
16. Fullerton DA, Jaggers J, Jones SD, et al. Adenosine for refractory pulmonary hypertension. Ann Thorac Surg 1996;62:874-7.
17. Fullerton DA, Jones SD, Grover FL, McIntyre RC Jr. Adenosine effectively controls pulmonary hypertension after cardiac operations. Ann Thorac Surg 1996;61:1118-23.
18. Palevsky HI. Therapeutic options for severe pulmonary hypertension. Clin Chest Med 1997;18:595-609.
19. Scott JP, Higenbottam T, Wallwork J. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pract 1990;44:231-4.
20. McLaughlin W, Genthner DE, Panella MM, Rich S. Decrease in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7.
21. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
22. Lindeborg DM, Kavanagh BP, Van Meurs K, Pearl RG. Inhaled nitric oxide does not alter the longitudinal distribution of pulmonary vascular resistance. J Appl Physiol 1995;78:341-8.
23. Meyrick B, Gamble W, Reid L. Development of Crotolaria pulmonary hypertension: hemodynamic and structural study. Am J Physiol 1980;239:H692-702.
24. Obbergh LJ, Charbonneau M, Blaise G. Combination of inhaled nitric oxide with i.v. nitroglycerin or with a prostacyclin analogue in the treatment of experimental pulmonary hypertension. Br J Anaesth 1996;77:227-31.
25. Walmrath D, Schermuly R, Pilch J, et al. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 1997;10:1084-92.
26. Chen EP, Bittner HB, David RD, Trigt PV. Right ventricular failure: insights provided by a new model of chronic pulmonary hypertension. Transplant 1997;63:209-16.
27. Katayama Y, Hatanaka K, Hayashi T, et al. Effects of inhaled nitric oxide in rats with chemically induced pulmonary hypertension. Respir Physiol 1994;97:301-7.
28. Mirza I, Nagamine J, Pearl RG. Additive effects of inhaled prostacyclin and inhaled nitric oxide in reducing experimental pulmonary hypertension [abstract]. Anesthesiology 1997;87: 1122.
29. Ichida F, Uese K, Hashimoto I, et al. Acute effect of oral prostacyclin and inhaled nitric oxide on pulmonary hypertension in children. J Cardiol 1997;29:217-24.
30. Parker TA, Ivy DD, Kinsella JP, et al. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Am J Respir Crit Care Med 1997;155:743-6.
31. Mikhail G, Gibbs J, Richardson M, et al. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension. Eur Heart J 1997;18:1499-504.
32. Hill LL, Pearl RG. Combined inhaled nitric oxide and inhaled prostacyclin during experimental chronic pulmonary hypertension. J Appl Physiol 1999;86:1160-4.